On September 10 the fourth pavilion at the Lenexpo Exhibition Complex
witnessed the official opening of the Import-Substitution and
Localisation Centre. The opening ceremony was attended by Valentina
Matvienko, Speaker of the Federation Council, Georgiy Poltavchenko, St.
Petersburg Governor, and Vyacheslav Makarov, Speaker of the St.
Petersburg Legislative Assembly.
The main objective of the Centre is to create an effective platform
for practical implementation of import substitution programmes aimed to
stimulate the localisation growth, facilitate the development of
enterprises in St. Petersburg and Northwestern Federal District and
build effective dialogue between the authorities and
manufacturers/suppliers and customers. The Centre will become the first
and unique communication site of this kind in Russia.
An exhibition area was organized in the Centre in order to demonstrate
the scientific, technological and production potential of enterprises.
After the grand opening ceremony, honourable guests took a tour around
The leading Russian pharmaceutical companies participated in the
exhibition: GEROPHARM Group of Companies presented the entire range of
the manufactured products on its stand: Cortexin®, Cortexin® for children (neurology), Retinalamin® (ophthalmology) - original. Russian drug products, and some generics important in terms of import substitution: Levetinol® and Memantinol®.
Honoured guests paid special attention to the genetically engineered human insulins: Rinsulin® R and Rinsulin®
NPH. These socially significant drug products are manufactured at the
GEROPHARM-Bio factory using full cycle principle: from the substance
synthesis to the finished dosage form, which guarantees stability of
product release and allows to perform complex quality control at all
production stages. Today these drug products are manufactured in all
modern product forms: vials, cartridges, autoinjectors and are supplied
to almost every region of Russia,
While showing drug samples to Valentina Matvienko, Speaker of the Federation Council, and Georgiy Poltavchenko, St. Petersburg Governor, Petr Rodionov has noted that today GEROPHARM is the only full-cycle manufacturer of insulins having such unique competences. The company plans to develop insulin analogues and their production technologies based on the full cycle principle. This will improve drug safety of the country and increase availability of socially significant drug products for patients.